{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:56:29Z","timestamp":1790690189761,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ebiom.2019.09.034","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T17:04:42Z","timestamp":1571677482000},"page":"58-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles"],"prefix":"10.1016","volume":"48","author":[{"given":"Sydney","family":"Dubois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Tesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Mareschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9636-8971","authenticated-orcid":false,"given":"Pierre-Julien","family":"Viailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Bohers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ruminy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascaline","family":"Etancelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Peyrouze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Copie-Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Petrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Jais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry Jo","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2019.09.034_bib0001","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0002","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0003","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0004","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0006","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and Chop chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0007","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0008","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","article-title":"Clinical impact of the cell-of-origin classification and the MYC\/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German high-grade non-hodgkin's lymphoma study group","volume":"35","author":"Staiger","year":"2017","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0009","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of Ibrutinib and Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0010","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0011","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-118519","article-title":"Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL): first safety, efficacy and biomarker analyses from the phase II CAVALLI st","volume":"132","author":"Morschhauser","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0012","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"3879","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0013","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","article-title":"Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing","volume":"122","author":"Morin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0014","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0015","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1158\/1078-0432.CCR-15-2305","article-title":"Next generation sequencing in diffuse large B cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA Study","volume":"22","author":"Dubois","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0016","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood-2013-08-460311","article-title":"Genome sequencing of lymphoid malignancies","volume":"122","author":"Mullighan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0017","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0018","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2011-05-326538","article-title":"The molecular pathogenesis of primary mediastinal large B-cell lymphoma","volume":"118","author":"Steidl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0019","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ccr.2012.07.014","article-title":"Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large b cell lymphoma","volume":"22","author":"Monti","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0020","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"13520","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0021","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0022","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0023","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large b cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002367","article-title":"Integrating genome-wide genetic variations and monocyte expression data reveals trans-regulated gene modules in humans","volume":"7","author":"Rotival","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/bioinformatics\/18.1.51","article-title":"Linear modes of gene expression determined by independent component analysis","volume":"18","author":"Liebermeister","year":"2002","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0026","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1371\/journal.pcbi.0030161","article-title":"Elucidating the altered transcriptional programs in breast cancer using independent component analysis","volume":"3","author":"Teschendorff","year":"2007","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0027","doi-asserted-by":"crossref","first-page":"16712","DOI":"10.18632\/oncotarget.3154","article-title":"Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?","volume":"6","author":"Dubois","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0028","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-16-1922","article-title":"Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P\u2013mutated diffuse large B-cell lymphoma: analysis of 361 cases","volume":"23","author":"Dubois","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0029","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1093\/bioinformatics\/btx309","article-title":"Application of the cghRA framework to the genomic characterization of diffuse large B-cell lymphoma","volume":"33","author":"Mareschal","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0030","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0031","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1200\/JCO.2009.22.7058","article-title":"Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study","volume":"27","author":"Copie-Bergman","year":"2009","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0032","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0033","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1200\/JCO.2013.54.9493","article-title":"Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte\/lympho","volume":"32","author":"Molina","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0034","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3109\/10428194.2013.767456","article-title":"Immunoglobulin heavy chain\/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma","volume":"54","author":"Jardin","year":"2013","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0035","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0036","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0105-2896.2006.00373.x","article-title":"A library of gene expression signatures to illuminate normal and pathological lymphoid biology","volume":"210","author":"Shaffer","year":"2006","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0037","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0038","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0039","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0040","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-b-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0041","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0042","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/leu.2010.302","article-title":"The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma","volume":"25","author":"Ruminy","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0043","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/gcc.22328","article-title":"Whole exome sequencing of relapsed\/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma","volume":"55","author":"Mareschal","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0044","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1158\/1078-0432.CCR-15-2305","article-title":"Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA Study","volume":"22","author":"Dubois","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0045","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/leu.2017.251","article-title":"Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets","volume":"32","author":"Karube","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0046","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0047","doi-asserted-by":"crossref","unstructured":"Chen B., Khodadoust M.S., Liu C.L., Newman A.M., Alizadeh A.A. Profiling tumor infiltrating immune cells with CIBERSORT. In: Methods in molecular biology (Clifton, N.J.). 2018: 243\u201359.","DOI":"10.1007\/978-1-4939-7493-1_12"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0048","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2015-03-632430","article-title":"Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL","volume":"126","author":"Offner","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0049","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.811.811","article-title":"Randomized phase 2 open-label study of R-CHOP \u00b1 Bortezomib in patients (Pts) with untreated non-germinal center B-Cell-like (Non-GCB) subtype diffuse large cell lymphoma (DLBCL): results from the pyramid trial (NCT00931918)","volume":"126","author":"Leonard","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0050","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1038\/bcj.2015.69","article-title":"Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma","volume":"5","author":"Novak","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ebiom.2019.09.034_bib0051","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase IB study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419306619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419306619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:56:30Z","timestamp":1762455390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396419306619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":51,"alternative-id":["S2352396419306619"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.09.034","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.09.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}